Newfield Therapeutics Corporation in conjunction with its academic partner, the Institute of Molecular Biosciences of Karl Franzens University in Graz, Austria is engaged in the development of novel cancer therapies.
International Patents for Newfield’s anti cancer peptides have recently been issued and apply to a broad range of solid tumors, exploiting the interaction between human lactoferricin derivatives and phosphatidylserine, expressed on the outside of cancerous cells. Phosphatidylserine has been described as a global marker for cancer cells and is the point of attack for the patented synthetic peptides derived from the innate human immune system. They have shown their effectiveness on a variety of human cancers, both in vitro and in vivo. In order to advance from the preclinical stage to clinical studies Newfield is entertaining additions to its existing partnerships.
7427 Matthews - Mint Hill Road, Sta. 105-212, Mint Hill, N.C. 28227